Literature DB >> 1243024

Substituted phenylacetylguanidines: a new class of antihypertensive agents.

J B Bream, H Lauener, C W Picard, G Scholtysik, T G White.   

Abstract

The synthesis of a new series of phenylacetylguanidines is described. Several of them exhibited high antihypertensive activity in the rat. The most potent member of the series is N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride [2,6-dichlorophenylacetylguanidine hydrochloride, compound 19], which is now in clinical study under the clinical code number BS 100-141. The structure-activity relationships in this class of compounds are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1243024

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

1.  Pharmacokinetics of guanfacine in patients undergoing haemodialysis.

Authors:  W Kirch; H Kohler; T Axthelm
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

2.  Elimination of guanfacine in patients with normal and impaired renal function.

Authors:  W Kirch; H Köhler; W Braun
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

3.  Comparison of the actions of centrally and peripherally administered clonidine and guanfacine in the rabbit: investigation of the differences.

Authors:  N D Barber; J L Reid
Journal:  Br J Pharmacol       Date:  1982-12       Impact factor: 8.739

4.  Evaluation of long-term treatment of essential hypertension with guanfacine.

Authors:  M Higuchi; A Overlack; K O Stumpe
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

5.  Comparative studies of guanfacine and methyldopa.

Authors:  A Roeckel; A Heidland
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

6.  The influence of renal function on plasma concentration, urinary excretion and antihypertensive effect of guanfacine.

Authors:  W Kirch; H Köhler; W Braun; C von Gizycki
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

7.  Acute and chronic renal effects of guanfacine in essential and renal hypertension.

Authors:  A Roeckel; A Heidland
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

Review 8.  Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy.

Authors:  Toyosaku Ota; Kazuhiko Yamamuro; Kosuke Okazaki; Toshifumi Kishimoto
Journal:  Drug Des Devel Ther       Date:  2021-05-11       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.